daclizumab


daclizumab

 [dah-kliz´u-mab] an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.

daclizumab

Dacliximab, Zenapax® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.